Xilio Therapeutics (XLO) Interest Expenses (2020 - 2022)

Xilio Therapeutics has disclosed Interest Expenses across 3 years of filings, most recently posting $129000.0 for Q1 2022.

• Interest Expenses for Q1 2022 came in at $129000.0, down 12.24% year-over-year; the trailing twelve-month figure through Dec 2022 was $129000.0 (down 77.84% YoY), and the FY2021 annual result was $756000.0, up 15.24% from the prior year.
• Interest Expenses came in at $129000.0 for Q1 2022 at Xilio Therapeutics, down from $145000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $290000.0 in Q3 2021 to a low of $129000.0 in Q1 2022.
• The 3-year median for Interest Expenses is $162000.0 (2020), against an average of $180666.7.
• Peak annual rise in Interest Expenses reached 47.96% in 2021, while the deepest fall reached 18.08% in 2021.
• Xilio Therapeutics' Interest Expenses stood at $177000.0 in 2020, then dropped by 18.08% to $145000.0 in 2021, then decreased by 11.03% to $129000.0 in 2022.
• The last three Interest Expenses figures came in at $129000.0 (Q1 2022), $145000.0 (Q4 2021), and $290000.0 (Q3 2021), per Business Quant data.